Astellas Pharma Inc. (TYO:4503)
Japan · Delayed Price · Currency is JPY 1,980.50
+2.50 (0.13%)
Nov 26, 2025, 2:35 PM JST
Astellas Pharma Employees
Astellas Pharma had 13,643 employees as of March 31, 2025. The number of employees decreased by 1,111 or -7.53% compared to the previous year.
Employees
13,643
Change (1Y)
-1,111
Growth (1Y)
-7.53%
Revenue / Employee
147.09M JPY
Profits / Employee
9.15M JPY
Market Cap
3.54T
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 13,643 | -1,111 | -7.53% |
| Mar 31, 2024 | 14,754 | 270 | 1.86% |
| Mar 31, 2023 | 14,484 | -38 | -0.26% |
| Mar 31, 2022 | 14,522 | -933 | -6.04% |
| Mar 31, 2021 | 15,455 | -428 | -2.69% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,455 |
| HOYA Corporation | 37,909 |
| Otsuka Holdings | 35,338 |
| Olympus | 29,297 |
| Daiichi Sankyo Company | 19,765 |
| M3, Inc. | 15,360 |
| Eisai | 10,917 |
| Kyowa Kirin | 5,669 |
Astellas Pharma News
- 4 days ago - Pfizer : FDA Oks PADCEV + Keytruda Combo For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer - Nasdaq
- 21 days ago - Q2 2026 Astellas Pharma Inc Earnings Presentation Transcript - GuruFocus
- 21 days ago - Full Year 2025 Astellas Pharma Inc Earnings Presentation Transcript - GuruFocus
- 4 weeks ago - Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA) - PRNewsWire
- 4 weeks ago - Astellas Pharma Announces Encouraging Data From OPTION-VMS Phase IV Study - Nasdaq
- 4 weeks ago - Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study - PRNewsWire
- 5 weeks ago - PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer - Benzinga
- 5 weeks ago - Astellas Reports Sustained GA Reduction With Long-Term IZERVAY Treatment In GATHER2 Extension Study - Nasdaq